相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Avivit Cahn et al.
DIABETES CARE (2020)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Effectiveness of sodium-glucose co-transporter-2 inhibitors on ischaemic heart disease
Yun Shen et al.
DIABETES OBESITY & METABOLISM (2020)
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
Shun Kohsaka et al.
Lancet Diabetes & Endocrinology (2020)
Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes
Ghadeer K. Dawwas et al.
DIABETES OBESITY & METABOLISM (2019)
Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors
Chintan V. Dave et al.
DIABETES OBESITY & METABOLISM (2019)
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Elisabetta Patorno et al.
CIRCULATION (2019)
Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes
Iliana C. Lega et al.
DIABETES OBESITY & METABOLISM (2019)
Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study
Bjorn Pasternak et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
Pedro Monteiro et al.
AGE AND AGEING (2019)
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study
Anna Norhammar et al.
DIABETES OBESITY & METABOLISM (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Diabetes Fact Sheets in Korea, 2018: An Appraisal of Current Status
Bo-Yeon Kim et al.
DIABETES & METABOLISM JOURNAL (2019)
2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea
Mee Kyoung Kim et al.
DIABETES & METABOLISM JOURNAL (2019)
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)
Patrick B. Ryan et al.
DIABETES OBESITY & METABOLISM (2018)
Drug treatment of heart failure in the elderly
D. Berliner et al.
HERZ (2018)
SGLT-2 Inhibitors and Cardiovascular Risk An Analysis of CVD-REAL
Matthew A. Cavender et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
Mikhail Kosiborod et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Management of diabetes in older adults
G. Sesti et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2018)
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Elisabetta Patorno et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Elisabetta Patorno et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World)
Jacob A. Udell et al.
CIRCULATION (2018)
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study
Frederik Persson et al.
DIABETES OBESITY & METABOLISM (2018)
Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials
Dandan Li et al.
DIABETES OBESITY & METABOLISM (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis
Santosh Gautam et al.
CARDIOVASCULAR DIABETOLOGY (2017)
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
Mikhail Kosiborod et al.
CIRCULATION (2017)
Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetese
Thomas Nystrom et al.
DIABETES OBESITY & METABOLISM (2017)
Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment
Marianna Noale et al.
ACTA DIABETOLOGICA (2016)
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013
Anna Norhammar et al.
DIABETOLOGIA (2016)
Predicting risk of adverse drug reactions in older adults
Amanda Hanora Lavan et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study
G. Marchesini et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2014)
SGLT inhibitors in management of diabetes
Abd A. Tahrani et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Diabetes Epidemics in Korea: Reappraise Nationwide Survey of Diabetes Diabetes in Korea 2007
Ie Byung Park et al.
DIABETES & METABOLISM JOURNAL (2013)
Diabetes in Older Adults
M. Sue Kirkman et al.
DIABETES CARE (2012)
Diabetes Mellitus in Older People: Position Statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes
Alan Sinclair et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION (2012)
Drug Trials for Older People
Richard I. Lindley
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2012)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
Sreenivasa Rao Kondapally Seshasai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
AG Bertoni et al.
DIABETES CARE (2004)
分享论文
